A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
Launched by CHIRON CORPORATION · Aug 30, 2001
Trial Information
Current as of March 23, 2025
Completed
Keywords
ClinConnect Summary
Patients will receive subcutaneous Proleukin in combination with ganciclovir and antiretroviral therapy, and the MTD will be determined.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • Documented HIV seropositivity.
- Prior Medication:
- Required:
- • FDA-approved antiretroviral therapy for at least 2 months prior to study entry.
- Allowed:
- • Prior G-CSF.
About Chiron Corporation
Chiron Corporation, a pioneering biotechnology company, specializes in the development and commercialization of innovative therapeutic solutions and diagnostic products. With a strong focus on infectious diseases and cancer, Chiron leverages advanced research and development to address unmet medical needs. The company is committed to clinical excellence and adheres to the highest standards of regulatory compliance, ensuring that its trials are conducted with integrity and scientific rigor. Through collaboration with healthcare professionals and academic institutions, Chiron Corporation strives to enhance patient outcomes and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toledo, Ohio, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials